期刊文献+

接受连续性静脉-静脉血液滤过患者左氧氟沙星抗感染方案的优化 被引量:4

Optimization of dosage regimens for levofloxacin in patients receiving continuous veno-venous hemofiltration
原文传递
导出
摘要 目的:对ICU肾衰竭接受连续性静脉-静脉血液滤过(continuous veno-venous haemofiltration,CVVH)治疗患者左氧氟沙星给药方案进行优化。方法:根据左氧氟沙星药效学及药动学参数等实验数据资料,应用蒙特卡洛模拟法计算累积反应分数(CFR),推荐最佳给药方案。结果:ICU肾衰竭接受CVVH治疗的患者,治疗肺炎克雷伯菌和肺炎链球菌感染时左氧氟沙星的最佳方案分别为500 mg qd iv和200 mg qd iv;ICU肾功能正常患者,对肺炎链球菌感染时左氧氟沙星的最佳方案为750 mg qd iv。对于肾衰竭或肾功能正常患者,当感染铜绿假单胞菌和金黄色葡萄球菌时,左氧氟沙星4种静注给药方案(200,300,500,750 mg qd)治疗效果均不佳,建议联合治疗或更换药物。结论:与ICU肾功能正常患者对比,ICU肾衰竭接受CVVH治疗患者使用左氧氟沙星时应根据不同病原菌感染考虑降低给药剂量。 OBJECTIVE To optimize dosage regimens of levofloxacin in patients receiving continuous veno-venous hemofil- tration (CWH). METHODS Pharmacodynamic and pharmacokinetic parameters of levofloxacin were gathered to calculate cumulative fraction of response (CFR) by Monte Carlo simulation (MCS) to recommend optimum dosage regimens. RESULTS The optimum dosage regimens of levofloxacin for patients receiving CVVH against Klebsiella pneurrvonia and Streptococcus pneumonia was 500 mg qd iv and 200 mg qd iv. The optimum dosage regimens for patients with normal renal functions in ICE against Streptococcus pneumonia was 750 mg qd iv. Combination therapy or alternative drugs should be con- sidered when 4 dosage regimens (200,300, 500, 750 mg qd) of levofloxacin were all ineffective against Pseudomonas aerugino sa and Staphylococcus aureus. CONCLUSION It is necessary to reduce close of levofloxaein in patient receiving CVVH accord- ing to infections caused by different bacteria comparing with patients with normal renal function in ICU.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2016年第3期216-218,共3页 Chinese Journal of Hospital Pharmacy
基金 天津市卫生局攻关课题(编号:13KG108)
关键词 左氧氟沙星 药动/药效学 CVVH 蒙特卡洛模拟 给药方案 levofloxacin PK/PD CVVH Monte Carlo simulation dosage regimens
  • 相关文献

参考文献15

  • 1Yun ZC,Su FT,Bai YC,et al. Pharmacokinetic-pharmacodynamic profiling of four antimicrobials against Gram-negative bacteria collected from Shenyang,China[J]. Bmc Infect Dis,2010,10(24):18-26. 被引量:1
  • 2Jiao Z,Jiang XG,Zhong MK. Clinical trial simulation[J]. Chin J New Drugs,2005,24(6):491-496. 被引量:1
  • 3Guenter SG,Iven H,Boos C,et al. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients[J]. Pharmacotherapy,2002,22(2):175-183. 被引量:1
  • 4何国鑫,叶可人,罗文朝,胡国新.左氧氟沙星在连续性静脉-静脉血液滤过时的药代动力学研究[J].实用医学杂志,2011,27(17):3204-3206. 被引量:2
  • 5唐发琴. 重症监护病房患者致病菌分布及耐药性临床分析[J]. 医学信息,2015,(1):1006-1959. 被引量:1
  • 6曹加,周兴培,孟玲. 蒙特卡洛模拟评价不同剂量的左氧氟沙星给药方案.中国药理学会药学监护专业委员会. 第二届第二次国际学术研讨会论文集[C]. 南京:2010. 被引量:1
  • 7Bouman C,Van-Kan H,Koopmans R,et al. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing[J]. Inten Care Med,2006,32(12):2013-2019. 被引量:1
  • 8陈欣,王莉,李英,冯婉玉.应用蒙特卡洛模拟评价和优化普外科抗菌药物给药方案[J].中国药学杂志,2013,48(4):309-313. 被引量:15
  • 9Kontou P,Manika K,Chatzika K,et al. Pharmacokinetics of moxifloxacin and high-dose levofloxacin in severe lower respiratory tract infections[J]. Inter J Antimicr Agents,2013,42(3):262-267. 被引量:1
  • 10Ambrose P,Grasela DT,Passarell J,et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections[J]. Antimicr Agents Chemother,2001,45(10):2793-2797. 被引量:1

二级参考文献24

  • 1张小江,王辉,徐英春,谢秀丽,陈民钧.重症监护病房最常见革兰阴性杆菌的耐药变迁[J].中华医院感染学杂志,2004,14(10):1179-1182. 被引量:32
  • 2焦正,蒋新国,钟明康,陆伟跃.药物临床研究的计算机模拟[J].中国新药与临床杂志,2005,24(6):491-496. 被引量:13
  • 3张菁,郁继诚,施耀国,周乐,叶信予,朱德妹,张婴元.左氧氟沙星药代动力学/药效学研究[J].中华医学杂志,2005,85(27):1926-1932. 被引量:60
  • 4史军.药物动力学和药效动力学在抗菌药物新药开发和临床治疗上的应用[J].中国临床药理学与治疗学,2007,12(2):121-133. 被引量:34
  • 5Mouton JW, Dudley MN, Cars O, et al. Standardization of pharmaeokinetic/ pharmacodynamic (PK/PD) terminology for antiinfective drugs: an update[J]. J Antimicrob Chemother, 2005, 55 (5) : 601-607. 被引量:1
  • 6David CY. Computational Chemistry [M]. John Wiley & Sons, Inc. 2001. 被引量:1
  • 7Kuti JL, Nightingatle CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: Data collected in North America in 2002[J]. Antimicrobial Agents and Chemotherapy, 2004,48 (7) : 2464-2470. 被引量:1
  • 8Frei RC, Wiederhold NP, Burgess DS. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic pharmacodynamie models with Monte Carlo simulation [J]. Journal of Antimicrobial Chemotherapy,2008,61(4):621-628. 被引量:1
  • 9Kuti JL, Horowita S, Nightingatle CH, et al. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem[J]. Pharmaeotherapy, 2005,25 (7) : 935-941. 被引量:1
  • 10Burgess DS, Frei CR. Comparison of β-lactam regimens for the treatment of Gramnegative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics [J]. Journal of Antimicrobial Chemotherapy, 2005, 56 (10): 893-898. 被引量:1

共引文献19

同被引文献34

引证文献4

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部